A very focused $20M start-up

Cancer BioScience Corp., a new company designed to bridge the worlds of pure science and applied medicine, is slated to be launched in October with initial capital of about $20 million from private individuals.

The Boston-based company will combine two newly popular concepts in company development: a disease focus and a "virtual company" structure. ...